<DOC>
	<DOCNO>NCT02931591</DOCNO>
	<brief_summary>This study aim determine Metformin treatment child bear small gestational age ( SGA ) treat Growth Hormone ( GH ) short stature improve response GH produce great concentration Insulin-like growth factor -1 ( IGF-1 ) blood .</brief_summary>
	<brief_title>Effect Insulin Sensitization IGF-1 Response Growth Hormone SGA Children</brief_title>
	<detailed_description>Growth hormone treatment ( GH ) recommend child bear small gestational age ( SGA ) fail catch-up . SGA heterogeneous condition reflect varied response GH treatment . Variable generation resistance Insulin-like growth factor-1 ( IGF-1 ) , important circulate mediator GH action may underpin heterogeneity . An association variant gene relate low insulin sensitivity reduce IGF-1 growth response GH therapy SGA child report recently . The hypothesis study insulin sensitivity may causally link response GH therapy , adjuvant therapy insulin sensitizer may improve IGF-1 generation , decrease IGF-I resistance optimise growth response . To explore hypothesis , study aim determine effect insulin sensitization use Metformin adjuvant fix dose GH therapy 6 month short SGA child . The patient short SGA child age 4 -10 year identify three paediatric endocrine unit Denmark , Ireland United Kingdom . In mechanistic study 24 subject start GH treatment randomise 1:1 ratio adjunctive Metformin placebo 6 month followed-up another 6months . The participant receive GH treatment entire duration study ( 12 month ) undergo oral glucose tolerance test dual-energy x-ray absorptiometry scan determine glucose metabolism body fat mass respectively baseline 6 month , 3 monthly measurement height , weight skinfold thickness . The primary outcome area curve IGF-1 level measure 0 , 1 , 3 6 month . Secondary outcome include change insulin sensitivity , height , body fat mass safety measure 6 12 month .</detailed_description>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>SGA child eligible GH treatment accord European Medicines Agency ( EMA ) The National Institute Health Care Excellence ( NICE ) criteria Gestational age birth &gt; 28 week Age 49 year girls 410 year boys Prepubertal start treatment Na√Øve GH therapy Known suspect allergy GH Previous participation GH trial Severe learn difficulty Previous active malignancy Benign intracranial hypertension</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Small gestational age</keyword>
	<keyword>insulin sensitivity</keyword>
	<keyword>IGF-1 response</keyword>
	<keyword>growth hormone treatment</keyword>
</DOC>